Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Makes 2nd Attempt At Virtual MDUFA Public Meeting

Executive Summary

For the second time in the past few months the US agency has rescheduled a webcast of a public meeting meant to start MDUFA V user-fee negotiations.

You may also be interested in...



Hahn Offers Upbeat User-Fee Prediction At AdvaMed Conference

The US FDA commish praised the medical device community's work in response to the COVID-19 pandemic and predicted that communication developed with industry during the crisis may ease upcoming MDUFA negotiations.

Spurred On By HHS Policy Shift, AdvaMed Chief Wants LDT Reform In User-Fee Negotiations

The medical device advocacy group plans to include laboratory developed test reform in their upcoming user-fee negotiations with the US FDA.

Webcasting The New Norm During COVID-19 As FDA Reschedules Opthalmic AdComm Panel

In a sign of the times, regulators are holding an advisory committee meeting for an ophthalmic device online because of the pandemic.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133148

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel